Regenerative Medicines: Bone and Joint Applications

Report Code: PHM032C

Publish Date: Jun 2013

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The U.S. market for regenerative medicine products used in bone and joint applications was estimated to total $2.72 billion in 2012 and is projected to increase to $2.73 billion in 2013. The market should total nearly $3.9 billion by 2018 and have a five-year compound annual growth rate (CAGR) of 7.3%.

Report Includes

  • An overview of the market for regenerative medicines in bone and joint applications, whose key objectives are the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process.
  • Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Coverage of other regenerative applications, such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care, as well as stem cell research.
  • Identification of market drivers, including an increase in diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth-stimulating agents in a regenerative appliance.
  • Descriptions of products, such as bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

STUDY SCOPE AND FORMAT

The U.S. has been the main regenerative medicine market both in terms of R&D innovation, patents, and product sales often accounting for as much as half of the market depending on the product niche; hence, the scope of the study is mainly the U.S., although global developments are discussed and measurements provided where relevant. The Overview section provides a background of the demographics underlying the market for bone and joint products, a definition of regenerative medicine and the technologies involved, and a discussion of regenerative products in development for applications other than bones and joints. Various application sections describe the leading bone and joint diseases and disorders applicable to regenerative technologies, including incidence and current methods of treatment.

The section on Products provides extensive descriptions and analyses (e.g., comparative analysis) of regenerative products used to treat bone and joint disorders, as well as a discussion of products in development.

The section on FDA clinical trials and newly approved products provides a discussion of regulatory issues affecting regenerative medicine products.

An extensive Company Profiles section provides estimates for the revenues of the leading companies and a concise description of leading and emerging companies in the area of regenerative products for bones and joints, including product introductions, patents, and overall business strategies.

ANALYST CREDENTIALS

Research analyst Kevin Gainer holds both B.A. and M.A. degrees in quantitative economic analysis, and has 25 years of economic and market research experience. He is the author of five published books; dozens of technical papers, analyses, and studies published in conference proceedings; and many unpublished reports within corporations. He has worked as a Research Editor and Project Analyst at BCC Research, and, over the last 25 years, has authored many BCC technology market research reports.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Regenerative Medicines: Bone and Joint Applications290Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY2Free
Chapter- 3: OVERVIEW AND OVERALL STATUS OF THE INDUSTRY13Free
Chapter- 4: PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE13Free
Chapter- 5: PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE17Free
Chapter- 6: STEM CELL THERAPIES AND REGENERATIVE MEDICINE17Free
Chapter- 7: REGENERATIVE PRODUCTS TO TREAT BONE DISEASES31Free
Chapter- 8: REGENERATIVE APPLICATIONS FOR BONES AND JOINTS36Free
Chapter- 9: ELECTRICAL BONE GROWTH STIMULATOR MARKET8Free
Chapter- 10: ORTHOPEDICS - FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT15Free
Chapter- 11: MARKET FOR TISSUE ENGINEERING PRODUCTS4Free
Chapter- 12: REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY6Free
Chapter- 13: SKIN TECHNOLOGIES3Free
Chapter- 14: NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE5Free
Chapter- 15: REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE6Free
Chapter- 16: REGENERATIVE MEDICINE AND DIABETES2Free
Chapter- 17: FDA APPROVED CLINICAL TRIALS INVOLVING REGENERATIVE MEDICINE21Free
Chapter- 18: OVERSEAS ACTIVITIES5Free
Chapter- 19: PATENT ANALYSIS12Free
Chapter- 20: C. CRAMER & CO. GMBH64Free
Chapter- 21: GLOSSARY OF KEY TERMS IN REGENERATIVE MEDICINE BUSINESS6Free
Published - Oct-2009| Analyst - Kevin Gainer| Code - PHM032B

Report Highlights

  • Overall sales in the regenerative medicine productsmarket were worth $1.1 billion in 2007, and remained flat into 2009. By 2014, sales are projected to increase to nearly $1.8 billion, for a 5-year compound annual growth rate (CAGR) of 8.6%.
  • The largest segment in the market, bone replacement/grafting, was valued at $714  million in 2007. This also has increased only slightly into 2009 but is projected to reach $979  million in 2014, for a 5-year CAGR of 6.3%.
  • Sales in the bone growth stimulators product segment were worth $321  million in 2007, and were to increase slightly into 2009.  By 2014, however, they are projected to increase to $578  million, for a 5-year CAGR of 11.9%.
Published - Jul-2003| Analyst - Lynn Gray| Code - PHM032A

Report Highlights

  • The total U.S. market for bone and joint applications of regenerative medicine is projected to rise at an average annual growth rate of 8.5% to reach $1.4 billion in 2007.
  • Regenerative medicine refers to technologies that repair or replace diseased or defective tissues or organs. The main types of regenerative medicine utilize products naturally occurring in the body, such as genes and proteins (antibodies, growth factors, hormones); cells and tissues; embryonic stem cells, and biomaterials. At present, most regenerative medicines on the market fall into the first category and include protein-based drugs and therapies containing human cells. However, there are a few products based on tissue engineering. This technology, which promises to be the most exciting and fastest growing sector of regenerative medicine in the near future, is the primary focus of this report. Tissue engineering technologies discussed include matrices and scaffolds, in vitro and in vivo technologies, and novel materials, which include those utilizing nanotechnology (atomic-scale engineering) of inorganic substances that meld with human tissues.

Related Reports

Biologic Therapeutic Drugs: Technologies and Global Markets

Published - Jan 2013 | Publisher - Jackson Highsmith | Code - BIO079B

The market for biologics was valued at $150 billion in 2011 and should reach $163 billion in 2012. Total market value is expected to reach $252 billion in 2017 after increasing at a five-year compound annual growth rate of 9%. 

Global Markets and Technologies for Cell and Tissue Analysis

Published - Jan 2013 | Publisher - Shalini Shahani Dewan | Code - BIO068B

The global cell and tissue analysis market was valued at $6.9 billion in 2011 and should reach $7.1 billion in 2012. Total market value is expected to reach $9.6 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 6.2%. 

Global Markets for Drug-Device Combinations

Published - Jan 2013 | Publisher - Kevin Gainer | Code - PHM045C

The market for global drug device combination products was valued at $18.5 billion in 2011 and should reach $19 billion in 2012. Total market value is expected to reach $30.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.9%.

Botanical and Plant-Derived Drugs: Global Markets

Published - Jan 2013 | Publisher - Kim Lawson | Code - BIO022F

The global botanical and plant-derived drug market was valued at $21.4 billion in 2011 and should reach $22.1 billion in 2012. Total market value is expected to reach $26.6 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 3.7%.

Recent Reports

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Active Pharmaceutical Ingredients: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM200C

The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.

Global Market for Contract Research Organization (CRO) Services

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM186C

The global market for contract research organization (CRO) services is expected to grow from $111.8 billion in 2024 and is projected to reach $166.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

Global Oncology Pharmaceuticals Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM256B

The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.

Excipients in Pharmaceuticals: Global Markets to 2029

Published - Sep 2024 | Publisher - Gundreddy Gopinadh | Code - PHM010M

The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.

Top Trending Reports

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Regenerative Medicines: Bone and Joint Applications
Customize Report